Purpose: Investigating some side effects of adjuvant capecitabine and oxaliplatin for gastric cancer after gastrectomy. Patients and Meqrods: Descriptive study on 45 patients have treated adjuvant chemotherapy by capecitabine and oxaliplatin in the Hanoi Medical University hospital and K hospital from January, 2011 to September, 2013. Results: Age 40; Male/female: 1.25/1. Time starting is 30.5 + or - 7.8 days; 97.8 percent of patients had completed 8 cycles; 100 percent of patients had used over 85 percent of chemotherapeutic standard dose. Neutropenia: 31.9 percent (grade 3.4: 2.2 percent); hematopenia: 41.6 percent (without seriously hematopenia); thrompocytopenia: 28.3 percent (without grade 3.4); increase AST/AL T: 47.6 percent (grade 3.4: 0.5 percent). Hyperbillirubinemia: 20.2 percent (grade 3.4: 4.8 percent); increase Creatinin: 3.4 percent (without grade 2-4). Peripheral neuropathy: 51 percent (without grade 3.4); Hand-foot syndrome: 46.7 percent (without grade 3.4); Decreased appetite: 40 percent (without grade 3.4); Nausea: 31.2 percent (without grade 3.4); Vomiting: 27.7 percent (without grade 3.4); Diarrhoea: 16.8 percent (without grade 3.4); Constipation: 4.5 percent (without grade 2-4); non loss hair. Conclusion: Xelox regimen is safely, has less seriously toxicity in adjuvant chemotherapy for gastric cancer patients.
- Đăng nhập để gửi ý kiến